OKYO Pharma Limited (OKYO)

NASDAQ: OKYO · Real-Time Price · USD

2.740

+0.140 (5.38%)

At close: Oct 31, 2025, 4:00 PM EDT

2.700

-0.040 (-1.46%)

After-hours: Oct 31, 2025, 7:58 PM EDT

OKYO Pharma Employees

OKYO Pharma had 4 employees as of March 31, 2025. The number of employees increased by 1 or 33.33% compared to the previous year.

Employees

4

Change (1Y)

1

Growth (1Y)

33.33%

Revenue / Employee

n/a

Profits / Employee

-$1,176,573

Market Cap

103.05M

Employees Chart

Employees History

Date	Employees	Change	Growth
Mar 31, 2025	4	1	33.33%
Mar 31, 2024	3	-5	-62.50%
Mar 31, 2023	8	1	14.29%
Mar 31, 2022	7	1	16.67%
Mar 31, 2021	6	2	50.00%
Mar 31, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Mar 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

OKYO News

15 days ago - OKYO Pharma Announces Chairman and Founder Acquires Shares - GlobeNewsWire
5 weeks ago - OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain - GlobeNewsWire
3 months ago - OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewsWire
5 months ago - Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited - Accesswire
5 months ago - OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit - GlobeNewsWire
6 months ago - OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewsWire
7 months ago - OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewsWire
9 months ago - OKYO Pharma Announces Chairman and CEO Acquire Shares - GlobeNewsWire